Abstract

The purpose of this paper is to compare the strategies of companies with data science practices and methodologies and the data specificities/variables that can influence the definition of a data science strategy in pharma companies. The current paper is an empirical study, and the research approach consists of verifying against a set of statistical tests the differences between companies with a data science strategy and companies without a data science strategy. We have designed a specific questionnaire and applied it to a sample of 280 pharma companies. The main findings are based on the analysis of these variables: overwhelming volume, managing unstructured data, data quality, availability of data, access rights to data, data ownership issues, cost of data, lack of pre-processing facilities, lack of technology, shortage of talent/skills, privacy concerns and regulatory risks, security, and difficulties of data portability regarding companies with a data science strategy and companies without a data science strategy. The paper offers an in-depth comparative analysis between companies with or without a data science strategy, and the key limitation is regarding the literature review as a consequence of the novelty of the theme; there is a lack of scientific studies regarding this specific aspect of data science. In terms of the practical business implications, an organization with a data science strategy will have better direction and management practices as the decision-making process is based on accurate and valuable data, but it needs data scientists skills to fulfil those goals.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call